Optipharm옵티팜

Optipharm is growing revenue but still loss-making, with the share price down over the past year.

Optipharm, a Korean animal health and diagnostics company, reported trailing twelve-month revenue of about ₩23.6B for the half year to June 2026, but operating and net losses persisted. Revenue has risen each year since 2021 while losses have narrowed from their 2021 peak, and the shares trade near the middle of their 52-week range after an 11.7% fall over one year.

What stands out

• Trailing revenue of ₩23.6B is up from ₩14.3B in 2021, with 2025 revenue growing 13.8% year on year.
• Trailing operating margin is -7.5% and net margin -9.5%, an improvement from -31.6% operating margin in 2021 but still negative.
• Cash of ₩4.0B sits against borrowings of ₩10.2B, and trailing free cash flow is about -₩0.6B.
• The company pays no dividend, and no fair value model or analyst targets are in the data; P/E is not meaningful given losses.
• Foreign ownership is steady at 0.8%, and the 20-day investor flows show small net retail selling of about ₩21M.

What to watch

• The full-year 2026 results and the next quarterly report, to see whether losses keep narrowing.
• Debt levels: borrowings exceed cash, and liabilities are 62.8% of equity.
• No recent news headlines are in the data; recent filings are mainly insider shareholding reports and routine meeting notices.